We are on a mission to change the way in which healthcare is provided by giving researchers the ability to closely examine the continuum from health to disease. In order to make this vision a reality, we brought together the most experienced management team, renowned scientists, industry leading investors and expert advisors, to form a collaborative ecosystem, united through the common goal of advancing the science of precision health.

 





Our broad portfolio of available kits spans multiple therapeutic areas including cardiology, infectious disease, inflammation, neurology, and oncology. Choose from our readily-available kits or our homebrew option.

Quanterix’ technology is designed to enable much earlier disease detection, better prognoses, and enhanced treatment methods to improve the quality of life and longevity of the population for generations to come.

The technology is currently being used for research applications in several therapeutic areas, including oncology, neurology, cardiology, inflammation and infectious disease.

Products

    Events

    Events not available

    News

    Health Management

    Measuring the Invisible: The Quanterix Revolution

    2025 22 Aug

    Quanterix is transforming biomarker detection with its Simoa® technology, enabling ultra-sensitive measurement of disease markers in blood. Its platforms (HD-X, SP-X® and SR-X®) support early diagnosis and research across neurology, oncology and more. Clinical validation, including in Alzheimer’s detection, demonstrates global relevance. Through1 Read more

    IMAGING Management

    Quanterix Expands Reach with IVD and Large Reference Labs

    2025 23 Jun

    Simoa Technology Advances Earlier Disease Detection by Measuring Signature Biomarkers   Quanterix Corporation, a company fueling scientific discovery through ultrasensitive biomarker detection, today announced that the HD-X Simoa Immunoassay Analyzer has received Class 1 Medical Device registration by the Ministry of Food and Drug Safety1 Read more

    IMAGING Management

    Quanterix to Present at Goldman Sachs Global Healthcare Conference

    2025 05 Jun

    Quanterix Corporation , a company fueling scientific discovery through ultrasensitive biomarker detection, today announced that President and Chief Executive Officer Masoud Toloue will present at the Goldman Sachs 46 th  Annual Global Healthcare Conference in Miami, Florida on Monday, June 9 th , at 1:20 p.m. ET.  Quanterix will also host one-on-1 Read more

    Health Management

    Advancing Early Alzheimer’s Detection with LucentAD® Complete

    2025 30 May

    LucentAD® Complete is a blood-based test that helps detect Alzheimer’s disease early using multiple biomarkers and a proprietary algorithm. Powered by Simoa® technology, it offers a non-invasive, accessible alternative to traditional methods. Available as an LDT, it supports clinical decision-making and streamlines trial recruitment by identifyi1 Read more

    Jobs not available

    Catalogue

      Catalogue not available

    900 Middlesex TPKE Billerica, MA 01821 USA,
    Billerica
    01821
    617 301 9400

    White Papers - Case Studies

    Not available

    Videos

      Videos not available

    Articles

    Health Management

    Measuring the Invisible: The Quanterix Revolution

    2025 22 Aug

    Quanterix is transforming biomarker detection with its Simoa® technology, enabling ultra-sensitive measurement of disease markers in blood. Its platforms (HD-X, SP-X® and SR-X®) support early diagnosis and research across neurology, oncology and more. Clinical validation, including in Alzheimer’s detection, demonstrates global relevance. Through1 Read more

    Health Management

    Advancing Early Alzheimer’s Detection with LucentAD® Complete

    2025 30 May

    LucentAD® Complete is a blood-based test that helps detect Alzheimer’s disease early using multiple biomarkers and a proprietary algorithm. Powered by Simoa® technology, it offers a non-invasive, accessible alternative to traditional methods. Available as an LDT, it supports clinical decision-making and streamlines trial recruitment by identifyi1 Read more

    Blog

    Not available